CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About CADTH What We Do Programs and Services CADTH Reimbursement Review Apremilast

Apremilast

Last Updated: March 31, 2015

Result type: Reports

Project Number: SR0437-000

Product Line: Reimbursement Review

Generic Name: Apremilast

Brand Name: Otezla

Manufacturer: Celgene

Therapeutic Area: Arthritis, psoriatic

Indications: Arthritis, psoriatic

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: December 17, 2015

Recommendation Type: List with criteria/condition

Apremilast

Files